MedWatch

Nordic Capital in talks to buy healthtech firm Inovalon

Private equity firm Nordic Capital is considering buying healthcare tech firm Inovalon Holdings.

Photo: Mark Lennihan

Private equity firm Nordic Capital is in advanced talks on a potential acquisition of healthcare technology company Inovalon Holdings Inc., according to people familiar with the matter.

A final agreement hasn’t been reached and discussions could still fall apart, said the people, who asked not to be identified because the information was private. Representatives for Nordic Capital and Inovalon didn’t immediately respond to requests for comment outside of normal business hours.

Shares in Inovalon have risen about 80 percent so far this year, giving it a market value of about USD 5.1bn.

Inovalon, based in Bowie, Maryland, went public in 2015 in an initial public offering that raised about USD 685m. The company’s software is used to aggregate and analyze health-care data from researchers and providers, according to its website.

Its database includes information from more than 1 million physicians, 580,000 clinical facilities and 336 million patients. The software is used by all of the top 25 US health plans as well as the world’s top 25 pharmaceutical companies, the company said.

Based in Stockholm, Nordic Capital has raised more than EUR 1.2bn (USD 1.4bn) for a new fund intended to invest EUR 35m to EUR 150m in healthcare, technology and financial services firms across northern Europe. On Monday, it agreed to invest in Dutch outpatient healthcare provider Equipe Zorgbedrijven.

Almirall opens submissions for new dermatology partnerships 

Dane overcomes Tokyo culture shock to run Lundbeck's most successful launch 

New chairman to prepare Leo Pharma for IPO with new launches and financial discipline 

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs